LINK Medical AS has acquired Finnish clinical research company CRST Oy , enhancing its early-phase clinical trial capabilities and strengthening its position in the Nordic market.

CRST, founded in 1995 as a University of Turku service unit, became independent in 2014. Operating clinics in Turku and Helsinki, CRST specializes in first-in-human (FIH), phase I, bioequivalence, and PK/PD studies across CNS, gastroenterology, metabolic, cardiovascular, and oncology research.

Anders Göransson , CEO of LINK Medical, stated: “This acquisition expands our early-phase services, allowing us to support clients from Phase I through Phase III, reinforcing our role as a leading Nordic CRO.”

CRST’s majority shareholder, UTU Holding Ltd., remains a minority shareholder in LINK Medical. Siru Helminen , CEO of UTU Holding Ltd., sees the partnership as an opportunity for international growth , while Anne Marjamäki, Chairman of CRST, highlights the synergies between both teams in accelerating drug development.

The acquisition will not affect clients , partnerships, or personnel , ensuring a seamless transition.

For more details, visit LINK Medical’s website.